NRx Pharmaceuticals Inc.

About NRx Pharmaceuticals Inc.

NRx Pharmaceuticals is a clinical biopharma company dedicated to developing breakthrough medicines for people with severe bipolar depression and PTSD, particularly in the presence of suicidality. Their mission is to bring hope to life through innovative treatments for life-threatening mental health conditions.

Products & Services

NRX-101:An investigational oral medication in FDA trials for suicidal bipolar depression, awarded fast track designation, breakthrough therapy designation, and a special protocol agreement by the FDA.

NRX-100 (Ketamine):An investigational drug under development for the treatment of acute suicidality.

Specialties

Suicidal Bipolar Depression Post-Traumatic Stress Disorder (PTSD) Chronic Pain NMDA Receptor Targeting Non-Hallucinogenic Treatments Non-Addictive Treatments Non-Neurotoxic Treatments

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 22300000 MR: - FA: $22.3 million FAN: 22300000	D: 2026-06-04 FD: 2026-06-04	-
2	RT: Public Offering T: - FT: Public Offering	A: 20000000 MR: - FA: $20.0 million FAN: 20000000	D: 2026-06-03 FD: 2026-06-03	-
3	RT: Series A T: - FT: Series A	A: 2500000 MR: - FA: $2.5 Million FAN: 2500000	D: 2025-04-03 FD: 2025-04-03	1 investors
4	RT: Series A T: - FT: Series A	A: 27000000 MR: - FA: $27 Million FAN: 27000000	D: 2025-01-28 FD: 2025-01-28	1 investors
5	RT: Equity and Debt T: - FT: Equity and Debt	A: 8900000 MR: - FA: 8.9 million FAN: 8900000	D: 2025-01-28 FD: 2025-01-28	1 investors
6	RT: Series A T: - FT: Series A	A: 27000000 MR: - FA: $27 Million FAN: 27000000	D: 2025-01-06 FD: 2025-01-06	1 investors
7	RT: Senior Secured Debt Financing T: - FT: Senior Secured Debt Financing	A: 16000000 MR: - FA: up to $16 million FAN: 16000000	D: 2024-08-13 FD: 2024-08-13	1 investors
8	RT: Underwritten Public Offering of Common Stock T: - FT: Underwritten Public Offering of Common Stock	A: 2000000 MR: - FA: $2.0 million FAN: 2000000	D: 2024-04-18 FD: 2024-04-18	1 investors
9	RT: Preferred Stock Purchase T: - FT: Preferred Stock Purchase	A: 1200000 MR: - FA: approximately $1.2 million FAN: 1200000	D: 2023-08-29 FD: 2023-08-29	1 investors
10	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 6280000 MR: - FA: $6.28 million FAN: 6280000	D: 2023-06-09 FD: 2023-06-09	-
11	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 6280000 MR: - FA: $6.28 million FAN: 6280000	D: 2023-06-06 FD: 2023-06-06	-

Public Offering Latest

2026-06-04

$22.3M

Public Offering 2026-06-03

$20.0M

Series A 2025-04-03

$2.5M

View 10 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jonathan C. Javitt

Founder, Chairman & Chief Scientist; Co-CEO HOPE Therapeutics

M

Michael Abrams

Chief Financial Officer

R

Rick Panicucci

Chief Technology Officer

M

Matthew Duffy

Chief Business Officer, NRx Pharmaceuticals; Co-CEO, Hope Therapeutics

M

Martin Brecher

Clinical & Safety Lead

P

Patrick Flynn

Chair of the Audit Committee and Chair of the Compensation Committee

View 17 more team members with Pro

Unlock Full Team Directory

Recent News